首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Acupoint Embedding of Polyglactin 910 Sutures in Patients with Chronic Pain due to Cervical Spondylotic Radiculopathy: A Multicenter, Randomized, Controlled Clinical Trial
【24h】

Acupoint Embedding of Polyglactin 910 Sutures in Patients with Chronic Pain due to Cervical Spondylotic Radiculopathy: A Multicenter, Randomized, Controlled Clinical Trial

机译:穴位埋置多聚凝乳肽910缝线治疗颈椎神经根性颈椎病慢性疼痛患者的多中心,随机对照临床试验

获取原文
       

摘要

Objective. We aimed to investigate the effectiveness of acupoint polyglactin 910 (PGLA) embedding in patients with cervical spondylotic radiculopathy (CSR). Methods. A total of 102 CSR patients with neck and shoulder pain were recruited and assigned randomly into three groups the sham acupoint embedding (SAE) group, the middle-layer acupoint PGLA embedding (MAPE) group, and the deep-layer acupoint PGLA embedding (DAPE) group. The primary outcomes were Visual Analog Scale (VAS) scores showing the analgesic effects of treatment. Secondary outcomes included clinical symptoms (evaluated by the Yasuhisa Tanaka 20 (YT-20) score and the neck disability index (NDI)) and patient health status (evaluated by the 36-item short-form survey (SF-36)) as reported in the trial. Results. Compared with the SAE group, VAS scores were significantly reduced at 1, 2, 3, 4, and 10 weeks after the first treatment in both the DAPE and MAPE groups (P < 0.001). Moreover, there were statistically significant increases in the weekly YT-20 scores and significant reductions of the weekly NDI scores compared with baseline values in both the DAPE and MAPE groups (P < 0.001). Compared with baseline values, both the physical component summary (PCS) and the mental component summary scores of the SF-36 at 2, 3, 4, and 10 weeks were significantly higher in the DAPE and MAPE groups (P < 0.001). There were significant lower VAS scores (P < 0.01), higher PCS scores (P < 0.05) at 3 weeks, and lower NDI scores (P < 0.05) at 4 weeks in the DAPE group compared with the MAPE group. Conclusions. Both DAPE and MAPE showed significant and long-lasting effects on alleviating pain and improving clinical symptoms as well as quality of life in CSR patients with neck and shoulder pain. A more intense effect was seen in the DAPE group compared with the MAPE group.
机译:目的。我们的目的是研究穴位聚乳酸素910(PGLA)嵌入在颈椎型神经根病(CSR)患者中的有效性。方法。总共招募了102例肩颈疼痛的CSR患者,并将其随机分为三组:假穴位埋入(SAE)组,中层穴位PGLA埋入(MAPE)组和深层穴位PGLA埋入(DAPE) )组。主要结果是显示治疗镇痛效果的视觉模拟量表(VAS)评分。次要结果包括报告的临床症状(由田中康久20(YT-20)得分和颈部残疾指数(NDI)评估)和患者健康状况(由36个项目的简短调查(SF-36)评估)在审判中。结果。与SAE组相比,DAPE组和MAPE组的首次治疗后第1、2、3、4和10周,VAS评分均显着降低(P <0.001)。此外,与DAPE组和MAPE组的基线值相比,每周YT-20评分在统计学上有显着增加,而每周NDI评分有显着降低(P <0.001)。与基线值相比,在DAPE和MAPE组中,SF-36在2、3、4和10周时的身体成分摘要(PCS)和精神成分摘要评分均显着更高(P <0.001)。与MAPE组相比,DAPE组在第3周时VAS评分(P <0.01)显着降低,在第3周时PCS评分(P <0.05)较高,在第4周时NDI评分(P <0.05)较低。结论。在患有颈肩痛的CSR患者中,DAPE和MAPE均对缓解疼痛和改善临床症状以及生活质量具有显着而持久的作用。与MAPE组相比,DAPE组的效果更明显。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号